title: Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases.
abstract: Gefitinib inhibits the epidermal growth factor receptor tyrosine kinase and improves survival in patients with non-small-cell lung cancer. We report 2 patients with extensive lytic bony metastasis in the spine and pelvis secondary to advanced pulmonary adenocarcinoma who were treated with gefitinib and had remarkable bone formation in the lytic bone lesions in the spine and pelvis. Surgery for stabilisation was avoided.
authors.affiliation: Elneelain University, Faculty of Medicine, Khartoum, Sudan.
authors.forename: Elrofai Suliman
authors.initials: ES
authors.lastname: Bashir
authors.affiliation: Department of Orthopaedic Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
authors.forename: Angel Khor Nee
authors.initials: AK
authors.lastname: Kwan
authors.affiliation: Department of Orthopaedic Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
authors.forename: Chris Yin Wei
authors.initials: CY
authors.lastname: Chan
authors.affiliation: Department of Orthopaedic Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
authors.forename: Kwan
authors.initials: K
authors.lastname: Mun Keong
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary*; D000077192:Adenocarcinoma of Lung; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000556:secondary*; D005260:Female; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D010012:Osteogenesis / Q000187:drug effects*; D010384:Pelvic Bones / Q000473:pathology; D011799:Quinazolines / Q000627:therapeutic use*; D013131:Spine / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib
keywords: adenocarcinoma of lung; bone cysts; gefitinib; neoplasm metastasis; receptor, epidermal growth factor